skip to main content
Visitante
Meu Espaço
Minha Conta
Sair
Identificação
This feature requires javascript
Tags
Revistas Eletrônicas (eJournals)
Livros Eletrônicos (eBooks)
Bases de Dados
Bibliotecas USP
Ajuda
Ajuda
Idioma:
Inglês
Espanhol
Português
This feature required javascript
This feature requires javascript
Primo Advanced Search
Busca Geral
Busca Geral
Acervo Físico
Acervo Físico
Produção Intelectual da USP
Produção USP
Primo Advanced Search Query Term
Input search text:
Show Results with:
criteria input
Qualquer
Show Results with:
Qualquer
Primo Advanced Search prefilters
Tipo de material:
criteria input
Todos os itens
Busca Geral
Busca Simples
This feature requires javascript
Mitochondria-targeted drugs for diabetic kidney disease
Mima, Akira
Heliyon, 2022-02, Vol.8 (2), p.e08878-e08878, Article e08878
[Periódico revisado por pares]
England: Elsevier Ltd
Texto completo disponível
Citações
Citado por
Exibir Online
Detalhes
Resenhas & Tags
Mais Opções
Nº de Citações
This feature requires javascript
Enviar para
Adicionar ao Meu Espaço
Remover do Meu Espaço
E-mail (máximo 30 registros por vez)
Imprimir
Link permanente
Referência
EasyBib
EndNote
RefWorks
del.icio.us
Exportar RIS
Exportar BibTeX
This feature requires javascript
Título:
Mitochondria-targeted drugs for diabetic kidney disease
Autor:
Mima, Akira
Assuntos:
Diabetic kidney disease (DKD)
;
Imeglimin
;
Metformin
;
Mitochondrial function
;
NFE-2 related factor 2 (Nrf2)
;
Reactive oxygen species (ROS)
;
Review
;
Sodium-glucose cotransporter 2 (SGLT2)
É parte de:
Heliyon, 2022-02, Vol.8 (2), p.e08878-e08878, Article e08878
Notas:
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição:
Diabetic kidney disease (DKD) is one of the most frequent causes of chronic kidney disease (CKD) in the United States. Chronic hyperglycemic conditions are thought to be the primary cause of DKD. However, it is clinically difficult to achieve glycemic control in individuals with diabetes. Recent advances in mitochondrial biology have provided a new understanding of mitochondrial dysfunction in DKD. Studies have revealed impaired mitochondrial function in a variety of diabetic complications, including DKD; moreover, abnormal mitochondrial fission may be involved in the progression of DKD. It has been reported that metformin or sodium-glucose cotransporter 2 (SGLT2) inhibitors may provide renal protection by improving mitochondrial dynamics and reducing oxidative stress. Thus, drugs that target the restoration of mitochondrial function may become novel therapeutic agents for DKD. Imeglimin is the first in a new class of oral antidiabetic drugs that can reduce reactive oxygen species production and increase mitochondrial DNA synthesis. This review outlines the potential therapeutic interventions that affect mitochondrial function and prevent DKD. Diabetic kidney disease (DKD), Imeglimin, Metformin, Mitochondrial function, NFE-2 related factor 2 (Nrf2), Reactive oxygen species (ROS), Sodium-glucose cotransporter 2 (SGLT2).
Editor:
England: Elsevier Ltd
Idioma:
Inglês
Links
View this record in MEDLINE/PubMed
This feature requires javascript
This feature requires javascript
Voltar para lista de resultados
Anterior
Resultado
6
Avançar
This feature requires javascript
This feature requires javascript
Buscando em bases de dados remotas. Favor aguardar.
Buscando por
em
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar o que foi encontrado até o momento
This feature requires javascript
This feature requires javascript